

Non-clinical study for developing a gene therapy of spinal cord injury using cell fate conversion

Stand Up Therapeutics



NEUROLOGY	Preclinical
Product Type	Gene/Cell Therapy & Nucleic acids
Indication	Chronic Spinal Cord Injury (ASIA-A and B grade)
Target	Non-neuronal cells (Astrocytic scar, Glial scar, fibroblasts and etc.)
MoA(Mechanism of Action)	Cell Fate Conversion (Direct lineage reprogramming)
Competitiveness	<ol style="list-style-type: none"> 1. Lower tumorigenicity issue compared cell-based therapy 2. High reprogramming efficacy compared conventional reprogramming technique 3. Low off-target issue through administration route 4. Secondary efficacy in reducing inflammatory response.
Development Stage	Preclinical
Route of Administration	Intrapatentymal injection in lesion site

Any unauthorized distribution or reproduction of this material is strictly prohibited.